Response to nutritional and growth hormone treatment in progeria

J E Abdenur1, W T Brown, S Friedman

  • 1Miami Children's Hospital, FL, USA.

Insights

Hutchinson-Gilford progeria syndrome (HGPS) is linked to elevated growth hormone (GH) and basal metabolic rate (BMR), causing failure to thrive. Treatments showed limited long-term benefits for growth and atherosclerosis.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Genetics

Background:

  • Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder with unknown molecular causes.
  • Patients exhibit failure to thrive (FTT), alopecia, scleroderma, joint stiffness, and severe atherosclerosis, with a median lifespan of 13 years.
  • Cardiovascular complications are the primary cause of mortality in HGPS.

Purpose of the Study:

  • To investigate the etiology of growth failure in HGPS through endocrine and metabolic studies.
  • To evaluate the response to nutritional therapy (NT) and growth hormone (GH) treatment in HGPS patients.

Main Methods:

  • Endocrine and metabolic assessments were conducted in five HGPS patients.
  • Nutritional therapy (NT) and GH treatment were administered to three patients.
  • Growth velocity (GV) and basal metabolic rate (BMR) were monitored.

Main Results:

  • Elevated GH levels and an increased BMR were characteristic findings in HGPS, potentially explaining FTT.
  • NT alone showed modest improvements in weight gain and GV.
  • Combined NT and GH treatment increased GV and growth factors but paradoxically decreased BMR, with diminishing responses over time.

Conclusions:

  • HGPS is associated with elevated GH and BMR, contributing to growth failure.
  • While NT and GH offer temporary benefits, they do not prevent the progression of atherosclerosis.
  • Further research is needed to understand the complex metabolic and endocrine aspects of HGPS.

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Cellular Adaptation III: Hyperplasia01:26

Cellular Adaptation III: Hyperplasia

Hyperplasia is an increase in the number of cells in a tissue or organ due to enhanced cell division. It is an adaptive, controlled response to stimuli such as injury, hormones, or stress, involving mitosis to produce genetically identical cells and support tissue repair and regeneration.Tissue CapacityCertain tissues, including the epidermis, intestinal epithelium, bone marrow, and fibroblasts, have a high potential for hyperplasia. Others, such as bone, cartilage, and smooth muscle, show...